XALATAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xalatan, and what generic alternatives are available?
Xalatan is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xalatan
A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.
Summary for XALATAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 76 |
| Patent Applications: | 6,239 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for XALATAN |
| What excipients (inactive ingredients) are in XALATAN? | XALATAN excipients list |
| DailyMed Link: | XALATAN at DailyMed |
Recent Clinical Trials for XALATAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rigshospitalet, Denmark | Phase 4 |
| Icahn School of Medicine at Mount Sinai | Phase 4 |
| CHA University | Phase 4 |
Pharmacology for XALATAN
| Drug Class | Prostaglandin Analog |
Anatomical Therapeutic Chemical (ATC) Classes for XALATAN
US Patents and Regulatory Information for XALATAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | AT | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XALATAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XALATAN
See the table below for patents covering XALATAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0569046 | Dérivés de prostaglandine pour traitement du glaucome ou hypertension oculaire (Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension) | ⤷ Try a Trial |
| Japan | S591418 | EICOSANOID AND DERIVATIVES FOR TREATING INTRAOCULAR ACCENTUATION AND GLAUCOMA | ⤷ Try a Trial |
| Germany | 3369068 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XALATAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3461484 | 132021000000068 | Italy | ⤷ Try a Trial | PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108 |
| 0364417 | 9690031-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST |
| 0364417 | SPC/GB97/014 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
